Literature DB >> 2655297

Clinical differences among nonsteroidal antiinflammatory drugs: implications for therapeutic substitution in ambulatory patients.

R A Levy1, D L Smith.   

Abstract

The practice of therapeutic substitution, i.e., replacing one drug with another chemically different drug from the same therapeutic class, represents an important therapeutic modification with potential clinical significance far beyond that of generic substitution. Adverse consequences following therapeutic substitution of nonsteroidal antiinflammatory drugs (NSAID) is of special concern because of substantial differences among these agents in pharmacokinetic, pharmacological, and clinical properties. Therapeutic substitution of NSAID for ambulatory patients may result in compromised clinical outcome because (1) patient response is unpredictable and selection of the optimal agent must be tailored for each patient; (2) substantial differences exist in adverse reaction profiles; (3) drug interaction studies are lacking; and (4) selection of an agent must be individualized to ensure compliance with the dosing regimen. Cost savings achieved through therapeutic substitution of NSAID may be lost by additional overall treatment costs due to adverse reactions or suboptimal therapy. The occurrence of adverse or suboptimal effects in ambulatory patients is more likely if NSAID are substituted without full knowledge of the patient's medical history and clinical status. Communication between the pharmacy and prescribing physician regarding a patient's specific needs is essential for rational substitution among NSAID.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2655297     DOI: 10.1177/106002808902300122

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  9 in total

1.  Clinical aspects of therapeutic substitution.

Authors:  R A Levy
Journal:  Pharmacoeconomics       Date:  1992       Impact factor: 4.981

2.  Therapeutic substitution: an option for cost-effective prescribing?

Authors:  S R Shulman; W Gouveia
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

Review 3.  Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  H A Wynne; M Campbell
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

Review 4.  Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis.

Authors:  W Bensen; A Zizzo
Journal:  Can Fam Physician       Date:  1998-01       Impact factor: 3.275

5.  Non-steroidal Anti-inflammatory Drugs: Monitoring to help prevent serious adverse effects.

Authors:  B Cardario; A A McKinnon
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

Review 6.  An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants.

Authors:  H Tannenbaum; P Davis; A S Russell; M H Atkinson; W Maksymowych; S H Huang; M Bell; G A Hawker; A Juby; S Vanner; J Sibley
Journal:  CMAJ       Date:  1996-07-01       Impact factor: 8.262

7.  Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta.

Authors:  D B Hogan; N R Campbell; R Crutcher; P Jennett; N MacLeod
Journal:  CMAJ       Date:  1994-08-01       Impact factor: 8.262

Review 8.  A composite screening tool for medication reviews of outpatients: general issues with specific examples.

Authors:  Peter A G M De Smet; Wilma Denneboom; Cees Kramers; Richard Grol
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  J R Brouwers; P A de Smet
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.